436 related articles for article (PubMed ID: 28574826)
1. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
2. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
3. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
4. Simiao Qingwen Baidu decoction inhibits Epstein-Barr virus-induced B lymphoproliferative disease and lytic viral replication.
Yang X; Liu L; Zhang H; Sun X; Yan Y; Ran R
Pharm Biol; 2021 Dec; 59(1):741-747. PubMed ID: 34155950
[TBL] [Abstract][Full Text] [Related]
5. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
6. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.
Thomé MP; Borde C; Larsen AK; Henriques JAP; Lenz G; Escargueil AE; Maréchal V
Antiviral Res; 2019 Dec; 172():104615. PubMed ID: 31580916
[TBL] [Abstract][Full Text] [Related]
7. A new compound, phomaherbarine A, induces cytolytic reactivation in epstein-barr virus-positive B cell lines.
Bae SE; Choi JW; Hong JW; Ku H; Sim KY; Ko GH; Jang DS; Shim SH; Park SG
Antiviral Res; 2024 Jul; 227():105906. PubMed ID: 38735576
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.
Anderson AG; Gaffy CB; Weseli JR; Gorres KL
Viruses; 2019 May; 11(5):. PubMed ID: 31108875
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro.
Jiang L; Zhang W; Li W; Ling C; Jiang M
Toxicol Lett; 2018 Jan; 282():154-165. PubMed ID: 29050931
[TBL] [Abstract][Full Text] [Related]
10. MYC Controls the Epstein-Barr Virus Lytic Switch.
Guo R; Jiang C; Zhang Y; Govande A; Trudeau SJ; Chen F; Fry CJ; Puri R; Wolinsky E; Schineller M; Frost TC; Gebre M; Zhao B; Giulino-Roth L; Doench JG; Teng M; Gewurz BE
Mol Cell; 2020 May; 78(4):653-669.e8. PubMed ID: 32315601
[TBL] [Abstract][Full Text] [Related]
11. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
12. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
Kalla M; Hammerschmidt W
Eur J Cell Biol; 2012 Jan; 91(1):65-9. PubMed ID: 21450364
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease.
Tanner JE; Menezes J
Blood; 1994 Dec; 84(11):3956-64. PubMed ID: 7949151
[TBL] [Abstract][Full Text] [Related]
14. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
Tanner JE; Alfieri C
Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
[TBL] [Abstract][Full Text] [Related]
15. Chaetocin reactivates the lytic replication of Epstein-Barr virus from latency via reactive oxygen species.
Zhang S; Yin J; Zhong J
Sci China Life Sci; 2017 Jan; 60(1):66-71. PubMed ID: 28063010
[TBL] [Abstract][Full Text] [Related]
16. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
17. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Fragoso YD; Brooks JB
Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
[TBL] [Abstract][Full Text] [Related]
18. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
[TBL] [Abstract][Full Text] [Related]
19. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
[TBL] [Abstract][Full Text] [Related]
20. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]